BTIG on Maze Therapeutics (MAZE): 'Stock Weakness Likely Due to Proteinuria Increases Seen in Two Diabetic Patienst
Tweet Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $46.00 price target on Maze Therapeutics (NASDAQ: MAZE).The analyst comments "Topline ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
